Skip to Content
Merck
All Photos(1)

Key Documents

OP16

Sigma-Aldrich

Anti-c-ErbB2/c-Neu (Ab-4) Mouse mAb (7.16.4)

liquid, clone 7.16.4, Calbiochem®

Synonym(s):

Anti-HER2, Anti-c-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.43

biological source

mouse

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

7.16.4, monoclonal

form

liquid

contains

≤0.1% sodium azide as preservative

species reactivity

rat, human

manufacturer/tradename

Calbiochem®

storage condition

do not freeze

isotype

IgG2a

shipped in

wet ice

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

human ... ERBB2(2064)

General description

Anti-c-ErbB2/c-Neu (Ab-4), mouse monoclonal, clone 7.16.4, recognizes ~185 kDa c-ErbB2 in overexpressing B104-1-1 cells. It is validated for WB, IP, ICC, frozen sections, & growth inhibition assay.
Purified mouse monoclonal antibody generated by immunizing C3H mice with the specified immunogen and fusing splenocytes with NS-1 mouse myeloma cells (see application references). Recognizes the ~185 kDa c-ErbB2/c-neu protein.
Recognizes the ~185 kDa c-ErbB2/c-Neu protein in overexpressing B104-1-1 cells.

Immunogen

B104-1-1 cells overexpressing rat c-ErbB2/c-Neu
Epitope: Within the extracellular domain
Human

Application


Frozen Sections (5 g/ml, see application references)
Immunoblotting (see application references)
Immunocytochemistry (5 g/ml)
Immunoprecipitation (1 g/ml, see application references)
Neutralization Studies (not recommended, see application references)

Packaging

Please refer to vial label for lot-specific concentration.

Warning

Toxicity: Standard Handling (A)

Physical form

In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.

Analysis Note

Negative Control
Fisher rat embryo cells
Positive Control
B104-1-1 cells

Other Notes

Stains frozen tissue sections of rat cells overexpressing c-neu. Does not inhibit in vitro protein-tyrosine kinase activity, but it will inhibit in vivo growth of tumors overexpressing the neu oncogene (see application references). Does not cross-react with the EGF receptor. Antibody should be titrated for optimal results in individual systems.
Zhang, H., et al. 1999. Exp. Mol. Pathol.67, 15.
Peterson, N,C., and Greene, M.I., 1988. DNA Cell Biol.17, 1031.
Kokai, Y., et al. 1988. Proc. Natl. Acad. Sci. USA85, 5389.
Van De Vijver, M.J., et al. 1988. New Engl. J. Med.319, 1239.
DiFiore, P.P., et al. 1987. Science237, 178.
Kokai, Y., et al. 1987. Proc. Natl. Acad. Sci. USA84, 8498.
Slamon, D.J., et al. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rebecca A Rozich et al.
Experimental and molecular pathology, 89(3), 248-259 (2010-07-27)
Cholangiocarcinoma, a severe form of biliary cancer, has a high mortality rate resulting partially from the advanced stage of disease at earliest diagnosis. A better understanding of the progressive molecular and cellular changes occurring during spontaneous cholangiocarcinogenesis is needed to
Michela Lizier et al.
Oncotarget, 7(38), 60793-60806 (2016-08-27)
Cell fusion between neoplastic and normal cells has been suggested to play a role in the acquisition of a malignant phenotype. Several studies have pointed to the macrophage as the normal partner in this fusion, suggesting that the fused cells
Kristina W Thiel et al.
Nucleic acids research, 40(13), 6319-6337 (2012-04-03)
Human epidermal growth factor receptor 2 (HER2) expression in breast cancer is associated with an aggressive phenotype and poor prognosis, making it an appealing therapeutic target. Trastuzumab, an HER2 antibody-based inhibitor, is currently the leading targeted treatment for HER2(+)-breast cancers.
Luiza I Hernandez et al.
Pharmaceuticals (Basel, Switzerland), 6(3), 295-319 (2013-07-31)
Recent clinical trials of small interfering RNAs (siRNAs) highlight the need for robust delivery technologies that will facilitate the successful application of these therapeutics to humans. Arguably, cell targeting by conjugation to cell-specific ligands provides a viable solution to this
Heather Gibson et al.
Oncoimmunology, 4(1), e984523-e984523 (2015-05-08)
The goal is to elucidate the immune modulating activity of an adenovirus (Adv) vector which showed therapeutic activity in human clinical trials. The oncolytic adenovirus (Adv/CD-TK) expressing two suicide genes was tested in two HER2/neu positive BALB/c mouse mammary tumor

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service